Description: Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Home Page: www.navamedic.com
Henrik Ibsensgate 100
Oslo,
0255
Norway
Phone:
47 67 11 25 40
Officers
Name | Title |
---|---|
Ms. Kathrine E. Gamborg Andreassen | Chief Exec. Officer |
Mr. Lars Hjarrand | Chief Financial Officer |
Mr. Ole Henrik Eriksen | Chief Operating Officer |
Ms. Astrid J. Torgersen Bratvedt | Chief Scientific Officer |
Mattias Von Hartmann | Marketing and Sales Director |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 70 |
Price-to-Book MRQ: | 3.0369 |
Price-to-Sales TTM: | 1.5734 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 28 |